Electrospun fiber patches for inflammatory skin diseases – Correlating in vitro drug release with ex vivo permeation

In this proof-of-concept study, we aimed to develop an anti-inflammatory patch that in contrast to the semi-solid standard therapy is dry and non-greasy, and only needs to be changed once a day due to continuous release of the active ingredient over 24 h. While fiber materials for the treatment of inflammatory skin diseases have been reported in the literature, the majority of studies focuses solely on material characterization including in vitro release studies; however, there is a lack of ex vivo permeation studies as well as comparison with standard therapy. However, such experiments are crucial to deduct the potential efficacy of the drug delivery system, as skin absorption of the drug may be the rate-limiting step and not the drug release. Therefore, we set out to investigate different types of electrospun fiber systems based on polycaprolactone, a polymer with a well-established safety profile widely used for fabricating electrospun patches. The electrospun fiber patches were loaded with the anti-inflammatory drug hydrocortisone and characterized not only for their drug release properties, but for the first time also for their skin permeation and retention as well as their cytocompatibility and anti-inflammatory properties on human skin. While in the release studies, the layer-by-layer fiber system proved to be best suited for an application time of 24 h, this was not reflected in the permeation studies, where all fiber systems showed a similar skin permeation and retention of the drug. In our study set-up, a comparison with standard cream formulations revealed that electrospun fibers offer an advantage in terms of the permeated amount of hydrocortisone. Overall, this study supports the importance of conducting comparisons with standard therapies and, additionally, confirms that electrospun fibers are a promising dosage form for the controlled release of anti-inflammatory drugs for the treatment of inflammatory skin diseases.